Top FDA Approvals of Oncology Therapies in 2024 - Cure Today
In 2024, FDA approved several cancer treatments including Elahere for gynecologic cancers, Udenyca biosimilar for on-body administration, Onivyde for metastatic pancreatic cancer, Enhertu for HER2-positive solid tumors, and Darzalex Faspro for multiple myeloma, based on clinical trial results showing improved survival and response rates.
Highlighted Terms
lenalidomidepegfilgrastim-cbqvplatinum-resistant epithelial ovariandexamethasoneEnhertufallopian tubedaratumumabmirvetuximab soravtansine–gynxbortezomibleucovorinmetastatic pancreatic adenocarcinomaHER2-positive solid tumorsfluorouracilirinotecan liposomebreast cancergynecologic cancerElahereRevlimidpancreatic cancerDarzalex Fasprohyaluronidase-fihjFDAoxaliplatinfam-trastuzumab deruxtecan-nxkipegfigrastimOnivydeUdenycamultiple myelomaNeulastaVelcadeprimary peritoneal cancer
Related News
Top FDA Approvals of Oncology Therapies in 2024 - Cure Today
In 2024, FDA approved several cancer treatments including Elahere for gynecologic cancers, Udenyca biosimilar for on-body administration, Onivyde for metastatic pancreatic cancer, Enhertu for HER2-positive solid tumors, and Darzalex Faspro for multiple myeloma, based on clinical trial results showing improved survival and response rates.